Moreover, LPA treatment in the cancer cells stimulated the CSC-related gene signature, via the PKD signaling (Figure 2D), including CD133 and CD44, two common CSC markers, whose expressions are connected with a poor prediction in pNET patients [49]. This evidence concerns the gene PRKD1 and cancer.